Search 

For more than 120 years, the Trade Commissioner Service (TCS) has been helping Canadian companies navigate international markets. Our trade commissioners in more than 160 cities worldwide can provide you with key business insights and access to an unbeatable network of international contacts. The TCS provides Canadian businesses and organizations with tailored advice to help them enter new markets outside of Canada.

InvivoSciences, Inc. (IVS) is a preclinical stage biotech company with a team of drug development experts, including Dr. Joseph Schlessinger, who developed various therapies including, a blockbuster drug - Sutent.
With an increasingly aging population with chronic diseases such as diabetes, heart failure is an urgent and critical challenge without an effective solution. There have been no successful phase III trials in worsening chronic heart failure or heart failure with preserved ejection fraction (HFpEF). Large clinical trials required for the heart failure trials have been the bottleneck. There is clear evidence showing that genetic factors drive heart failure development. Our mission is to cure heart failure one gene at a time.
We have leveraged our advanced artificial intelligence integrated breakthrough in precision medicine discovery platform using patient-derived human micro heart on a chip, NuHeart™, to identify and validate multiple drug pipelines rapidly as well as help us to determine biomarkers and stratify the patients for a clinical trial recruitments. Our precision heart failure pipelines are at least ten times more cost-effective to develop, especially during their clinical stages. Using our platform, we have developed two pipelines of small-molecule candidates for difficult to treat, genetically defined heart failure conditions. Our Pipelines of precision medicines have the potential to deliver better outcomes for patients fighting hard to treat heritable heart disease.
Collaborative patient-driven precision medicine-based drug development empowered with our novel platform will lead to meaningfully better outcomes for heart failure patients, which we refer to as InvivoSciences’ discovery engine to develop target therapies. Our lead program includes candidates in preclinical development for monogenetic heart failures. To date, IVS raised $8.5 Million non-dilutive funding from founders, board, commercial contracts, and grants. The funds have been used to create a portfolio of assets (breakthrough discovery platform, NuHeart™, three genetically defined disease models, current discovery programs, and a strong portfolio of patents including both US and international.
To join and support our drug discovery programs forward, InvivoSciences is seeking world-class life science investors and strategic partners for our Series A round for growth capital for $10 M in two trunches for commercial growth and accelerating our drug program.

We are a corporate finance firm committed to advancing the field of Healthcare through advisory,and investments.

We advise and buy-side and sell side corporates and Family offices on investment in Healthcare & life Sciences across Switzerland, Europe and the US.

Olympus was founded in 1919 and launched our first gastro-camera in the 1950s. Since then, Olympus developed into a MedTech leader, designing and delivering innovative solutions for medical and surgical procedures, especially in the field of endoscopy.

High-content screening for AI-drug discovery